Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKainos Group Regulatory News (KNOS)

Share Price Information for Kainos Group (KNOS)

Share Price is delayed by 15 minutes
Get Live Data
826.00    0.00 (0.00%)
Bid:
827.50
Ask:
830.00
Spread: 2.50 (0.302%)
Market Cap: £951.34m
KNOS Live PriceLast checked at - London Stock Exchange

Intraday Kainos Group Share Chart

Trading Update

6 Sep 2016 07:00

RNS Number : 0050J
Kainos Group plc
06 September 2016
 

 

ANNOUNCEMENT

6 September 2016

 

Kainos Group plc

("Kainos" or "the Group")

Trading Update

 

- Group maintains guidance for current year -

 

Kainos Group plc (KNOS), a leading UK-based provider of IT, consulting and software solutions, today issues a trading update for the period from 1 April 2016 to 31 August 2016.

 

In the Digital Services division, the Group is experiencing good growth in the public sector. Demand from central and regional government clients continues to strengthen, with notable new contract wins at the National Offender Management Service and the Home Office.

 

Demand for WorkSmart services is strong in the UK and mainland Europe, where the Group has added a number of new enterprise clients, including Tullett Prebon Group Limited. Take-up of the Group's SaaS-based automated testing product, Smart, is solid and the Group continues to invest in both product development and sales and marketing for Smart.

 

The Evolve division continues to make progress with its Integrated Care SaaS platform and has signed a five-year subscription agreement with Hygieia to use Evolve to power its insulin therapy navigation application which aims to help diabetics systematically manage their changing insulin requirements. In the UK, the Evolve for iPad™ offering, which allows clinicians to access electronic patient records on the move, is now in live operation at the South East Coast Ambulance Service. Market conditions in the NHS remain challenging, with limited additional funding to drive demand.

 

Although the outcome of the UK's referendum on Europe ('Brexit') brings with it some uncertainties, the Group continues to see immediate opportunities for growth.

 

Kainos has a robust balance sheet with strong reserves, no debt and strong cash generation, as well as a growing level of recurring revenue. The Group expects results for the full year to be in line with market expectations.

 

 

 

 

-ENDS-

 

For further information, please contact:

 

Kainos via FTI Consulting LLP

Brendan Mooney, Chief Executive Officer

Brian Gannon, SVP Corporate Development

 

Investec Bank plc +44 20 7597 5970

Dominic Emery/Sebastian Lawrence

Patrick Robb/Matt Lewis

 

FTI Consulting LLP +44 20 3727 1000

Matt Dixon/Chris Lane

 

About Kainos

Kainos is a UK-based provider of IT services, consulting and software solutions. It specialises across multiple sectors in the development of digital technology solutions, including software design and agile software development. The Group's Evolve Electronic Medical Records (EMR) product provides a market-leading comprehensive suite of digital services to healthcare providers such as hospitals and community care organisations. Kainos has also developed an automated testing product, Smart, to complement its Workday implementation services.

 

Kainos Group plc (KNOS) is listed on the main market of the London Stock Exchange. At 31 March 2016, it had almost 800 staff working in eight offices in the USA, UK, Ireland, Poland and the Netherlands.

 

For further information please visit the company website: https://www.kainos.com/

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLAMFTMBBMBFF
Date   Source Headline
18th Nov 20247:00 amRNSTransaction in Own Shares
15th Nov 20247:00 amRNSTransaction in Own Shares
13th Nov 20247:00 amRNSTransaction in Own Shares
12th Nov 202412:32 pmRNSDirector / PDMR shareholdings
11th Nov 20247:01 amRNSShare buyback programme
11th Nov 20247:00 amRNSInterim Results
31st Oct 20247:00 amRNSTrading Update
1st Oct 20249:49 amRNSTotal Voting Rights
24th Sep 20241:11 pmRNSBoard Changes
24th Sep 20241:06 pmRNSResults of Annual General Meeting
9th Sep 202410:14 amRNSHolding(s) in Company
2nd Sep 202411:13 amRNSTotal Voting Rights
2nd Sep 20247:00 amRNSTrading Statement
15th Aug 202410:00 amRNSNotice of AGM
1st Aug 202410:34 amRNSTotal Voting Rights
31st Jul 20244:41 pmRNSAnnual Report 2024
25th Jul 20242:30 pmRNSWorkday Partnership & Co-Sell drives £200m Target
11th Jul 202410:26 amRNSTR-1: Notification of major holdings
2nd Jul 20249:57 amRNSDirector / PDMR shareholdings
1st Jul 20249:23 amRNSTotal Voting Rights
3rd Jun 20243:53 pmRNSDirector/PDMR Shareholding
3rd Jun 202410:36 amRNSTotal Voting Rights
20th May 20247:01 amRNSBoard and Board Committee Changes
20th May 20247:00 amRNSFull year results
1st May 202412:00 pmRNSTotal Voting Rights
15th Apr 20247:00 amRNSYear-end Trading Update
11th Apr 20243:50 pmRNSHolding(s) in Company
2nd Apr 202412:12 pmRNSTotal Voting Rights
15th Mar 20241:48 pmRNSHolding(s) in Company
28th Feb 20243:16 pmRNSHolding(s) in Company
5th Feb 202412:51 pmRNSHolding(s) in Company
1st Feb 20244:29 pmRNSHolding(s) in Company
1st Feb 20244:21 pmRNSHolding(s) in Company
1st Feb 202412:13 pmRNSTotal Voting Rights
31st Jan 20244:09 pmRNSDirector/PDMR Shareholding
2nd Jan 202412:15 pmRNSTotal Voting Rights
22nd Dec 20239:21 amRNSExecutive Director PSP Award/PDMR shareholdings
1st Dec 20239:35 amRNSTotal Voting Rights
17th Nov 202311:13 amRNSExecutive Director PSP Award/PDMR shareholdings
13th Nov 20237:00 amRNSInterim Results
1st Nov 202310:48 amRNSTotal Voting Rights
2nd Oct 202312:41 pmRNSTotal Voting Rights
2nd Oct 20237:00 amRNSConfirmation of Board Changes
27th Sep 20235:52 pmRNSDirector/PDMR Shareholding
21st Sep 20232:54 pmRNSResults of Annual General Meeting
21st Sep 202311:59 amRNSConfirmation of CEO appointment
1st Sep 202312:34 pmRNSTotal Voting Rights
31st Aug 20237:00 amRNSTrading Update
10th Aug 20232:48 pmRNSNotice of AGM
3rd Aug 202310:41 amRNSMount Charles & Bankmore Square, Belfast

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.